Clinical trial · Interventional
Surgery or Chemoradiotherapy for Cervical Esophageal Cancer
Surgery Versus Definitive Chemoradiotherapy for Resectable Cervical Esophageal Squamous Cell Carcinoma: A Prospective Multicenter Open-Label Clinical Trial
NCT05327517CI-TRIAL-00057804recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare surgery with definitive chemoradiotherapy for patients with resectable cervical esophageal squamous cell carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Esophageal Cancer | Esophageal Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Esophagectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Surgery
- description
- Patients receive esophagectomy or neoadjuvant therapy plus esophagectomy
- interventionNames
- Procedure: Esophagectomy
- type
- ACTIVE_COMPARATOR
- label
- Definitive chemoradiotherapy
- description
- Patients receive definitive chemoradiotherapy
- interventionNames
- Procedure: Esophagectomy
Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- 5 years after surgery or definitive Chemoradiotherapy is completed
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with resectable cervical esophageal squamous cell carcinoma (cT1b-T4aN0-3M0); * Cervical esophageal cancers spreads upwards to involve the hypopharynx and downwards to involve the thoracic esophagus can also be included; * Aged 18-75 years; * Without any contraindication of operation; * Hemoglobin \>=90 g/L; Leukocytes \>=4.0x10\^9/L; Absolute neutrophil count \>=1.5x10\^9/L; Platelet \>=100x10\^9/L;Total bilirubin \<=1.5 ULN; ALT \<=2.5 ULN; AST \<=2.5 ULN; Serum creatinine \<=1.5 ULN or creatinine clearance rate \>=50 mL/min (Cocheroft-Gault);INR \<=1.5 ULN; APTT \<=1.5 ULN; * Without other malignancies; * Expected R0 resection; * ECOG PS 0-1; * Volunteered to participate in the study, signed the informed consent form. Exclusion Criteria: * Without other malignancies; * With mental diseases; * With hemorrhagic disease; * Inoperable patients; * Pregnant or lactating women; * Has a history of allergy to paclitaxel or cisplatin
References
Publications (0)
Data not yet available
No reference posted for this study.